{"id":"W2563521219","doi":"10.1182/blood.v114.22.303.303","title":"PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Royal Victoria Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Bortezomib; Clinical endpoint; Phases of clinical research; Refractory (planetary science); Internal medicine; Multiple myeloma; Proteasome inhibitor; Oncology; Pharmacology; Adverse effect; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002284686,0.001341145,0.001705391,0.0006879518,0.0004628384,0.0008862477,0.0009572154,0.0009790979,0.003632138],"category_scores_gemma":[0.000945888,0.0006249481,0.0008803735,0.00068238,0.0007399314,0.001025096,0.000409909,0.002735839,0.00103769],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000741035,"about_ca_system_score_gemma":0.001424622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000936924,"about_ca_topic_score_gemma":0.002568471,"domain_scores_codex":[0.9994125,0.000288244,0.0000305067,0.00007491052,0.00008605733,0.0001078238],"domain_scores_gemma":[0.9990786,0.0001576118,0.0002482274,0.00006462739,0.00007218836,0.0003787237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6012837,0.06168603,0.04638817,0.001692003,0.003568213,0.0008519206,0.0006981743,0.003029879,0.0917179,0.0003818921,0.01358654,0.1751155],"study_design_scores_gemma":[0.4794952,0.3886019,0.1112893,0.00006468269,0.001601281,0.001183359,0.0001396957,0.001435262,0.006025945,0.0003416177,0.009738031,0.00008373755],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865395,0.002952455,0.0005649785,0.0004160669,0.00008509807,0.002723203,0.004300389,0.0001415345,0.002276649],"genre_scores_gemma":[0.9732878,0.002588225,0.00246359,0.001225131,0.0002275021,0.003192217,0.01412215,0.00005922929,0.002834157],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003632138,"threshold_uncertainty_score":0.0121507,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04783097950502423,"score_gpt":0.3235842274055434,"score_spread":0.2757532479005191,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}